Allain, Eric P.
Rouleau, Michèle
Vanura, Katrina
Tremblay, Sophie
Vaillancourt, Joanie
Bat, Vincent
Caron, Patrick
Villeneuve, Lyne
Labriet, Adrien
Turcotte, Véronique
Le, Trang
Shehata, Medhat
Schnabl, Susanne
Demirtas, Dita
Hubmann, Rainer
Joly-Beauparlant, Charles
Droit, Arnaud
Jäger, Ulrich
Staber, Philipp B.
Lévesque, Eric
Guillemette, Chantal
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research (FRN-152986, FRN-408093)
Article History
Received: 8 August 2019
Revised: 2 April 2020
Accepted: 23 April 2020
First Online: 18 May 2020
Ethics approval and consent to participate
: The study was carried out in accordance with the Declaration of Helsinki. Patients provided informed consent and the study was approved by the local ethical research committees of the Medical University of Vienna (Ethics vote 1499/2015) and the CHU de Québec (A14-10-1205).
: Not applicable.
: The datasets generated during the current study are available in the Gene Expression Omnibus repository with the accession number GSE135030.
: The authors declare no competing interests.
: The Cancer Research Society, the Leukemia and Lymphoma Society of Canada, the Canadian Institutes of Health Research (CIHR; FRN-152986 (C.G. and E.L.) and FRN-408093 (C.G.)), and the Canada Research Chair Program financially supported this study. E.P.A. was supported by scholarships from the Fonds de Recherche du Québec—Santé (FRQS), Université Laval foundation—Leadership and sustainable development award, CHU de Québec foundation—Fernand Labrie excellence award. J.V. and A.L. were each supported by a scholarship from the FRQS. C.G. holds a Canada Research Chair in Pharmacogenomics from the CIHR.